ArticleMacromolecular bioscience2026
Enzyme-Responsive Composite Hydrogel Coating Containing Nano-HA/Nano-ZnO with Pro-Osteogenic and Anti-Osteoclastic Properties.
Article in Macromolecular bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The treatment of osteoporotic bone defects remains challenging due to the pathological microenvironment with impaired regenerative capacity and imbalanced bone formation and resorption. In this study, a methacrylated gelatin (GelMA) and methacrylated chitosan (CSMA) composite hydrogel coating is developed on poly(phthalazinone ether nitrile ketone) (PPENK), showing pro-osteogenic and anti-osteoclastic effects in vitro. Nano-zinc oxide (nano-ZnO), nano-hydroxyapatite (nano-HA), and phosphate-ester-functionalized alendronate (ALNP) are incorporated to confer antibacterial activity, promote osteogenesis, and enable enzyme-responsive release of anti-osteoporosis alendronate (ALN). SEM/EDS results confirm the homogeneous dispersion of the nanoparticles within the porous hydrogel. The stability of the hydrogel coating is verified by smooth scratch edges and no visible detachment in the cross-hatch test. ALN release experiments confirm that the release amount of ALN is positively correlated with alkaline phosphatase (ALP) concentration, indicating significant enzyme-responsive characteristics. In vitro studies show that the hydrogel coating on PPENK exhibits antibacterial activity. Nano-HA and nano-ZnO enhance the expression of osteogenic-related genes and proteins in MC3T3-E1 pre-osteoblasts. The released ALN inhibits the receptor activator of nuclear factor-κB ligand (RANKL)-induced differentiation of RAW264.7 macrophages into osteoclasts. Overall, this surface modification strategy integrates enzyme-responsive ALN release with composite hydrogel coating on PPENK, realizing antibacterial, osteogenic, and anti-osteoclastic effects in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.